Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: A perspective from SITC and AACR

Nicholas L. Bayless, Jeffrey A. Bluestone, Samantha Bucktrout, Lisa H. Butterfield, Elizabeth M. Jaffee, Christian A. Koch, Bart O. Roep, Arlene H. Sharpe, William J. Murphy*, Alexandra Chloé Villani*, Theresa L. Walunas*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are well-recognized side effects of some of the most effective cancer immunotherapy agents, including antibody blockade of the cytotoxic T-lymphocyte-associated protein 4 and programmed death protein 1/programmed-death ligand 1 pathways. To develop an action plan on the key elements needed to unravel and understand the key mechanisms driving irAEs, the Society for Immunotherapy for Cancer and the American Association for Cancer Research partnered to bring together research and clinical experts in cancer immunotherapy, autoimmunity, immune regulation, genetics and informatics who are investigating irAEs using animal models, clinical data and patient specimens to discuss current strategies and identify the critical next steps needed to create breakthroughs in our understanding of these toxicities. The genetic and environmental risk factors, immune cell subsets and other key immunological mediators and the unique clinical presentations of irAEs across the different organ systems were the foundation for identifying key opportunities and future directions described in this report. These include the pressing need for significantly improved preclinical model systems, broader collection of biospecimens with standardized collection and clinical annotation made available for research and integration of electronic health record and multiomic data with harmonized and standardized methods, definitions and terminologies to further our understanding of irAE pathogenesis. Based on these needs, this report makes a set of recommendations to advance our understanding of irAE mechanisms, which will be crucial to prevent their occurrence and improve their treatment.

Original languageEnglish (US)
Article numbere002627
JournalJournal for immunotherapy of cancer
Issue number9
StatePublished - Sep 3 2021


  • autoimmunity
  • immunotherapy
  • translational medical research

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Immunology and Allergy
  • Pharmacology
  • Immunology


Dive into the research topics of 'Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: A perspective from SITC and AACR'. Together they form a unique fingerprint.

Cite this